AIM 4: To study the role of the pre-established panel of molecular markers in the early detection of CAN in patients receiving mycophenolate mofetil (MMF) as immunosuppressive treatment, we will study urine and PBMC samples from patients more than 12 months post-transplantation, with normal creatinine, and proteinuria.